Instituto Português de Oncologia do Porto Dr Francisco Gentil, E.P.E; Centro Hospitalar de São João, E.P.E
Prostate cancer is the most prevalent in men in developed countries and presents high survival rates. Hormone therapy (Androgen Deprivation Therapy) is one of the most commonly used treatment for this cancer, and about half of prostate cancer patients are estimated to undergo this treatment during the course of the disease.
This project aims to study one of the possible adverse effects of hormone therapy: cognitive decline.
Thus, in February 2018, ISPUP started a cohort of patients with prostate cancer at the Portuguese Institute of Oncology of Porto Dr Francisco Gentil, EPE and at the São João Hospital Center, EPE, to evaluate the variation in cognitive performance from before to after treatments.
The cognitive function will be evaluated with the screening test Montreal Cognitive Assessment and with the new web remote monitoring tool Brain on Track that allows a serial evaluation of the cognitive performance, resulting in a more robust assessment of the cognitive function.
This project received funding from the Foundation for Science and Technology.
Funding approved by the Competitiveness and Internationalization Operational Program in its FEDER component, by the Foundation for Science and Technology, I.P.
